上海交通大学学报（医学版）

上海交通大学学报（医学版） >

2017 , Vol. 37 >Issue 5: 652

DOI: https://doi.org/10.3969/j.issn.1674-8115.2017.05.016

论著（临床研究）

康柏西普对糖尿病性黄斑水肿的疗效评价

  • 孙清磊 ,
  • 闫焱 ,
  • 祝丽娜 ,
  • 秦晓玲 ,
  • 谭烨 ,
  • 刘洁 ,
  • 谭海波 ,
  • 宁利 ,
  • 柳林
展开
  • 1.上海交通大学 医学院附属仁济医院眼科，上海 200127；2.上海市浦东新区陆家嘴社区卫生服务中心眼科，上海 200120；3.上海市浦东新区公利医院眼科，上海 200135；4.上海市浦东新区潍坊社区卫生中心眼科，上海 200122
孙清磊（1990—），男，住院医师，硕士生；电子信箱：conansun1990@163.com。

网络出版日期: 2017-05-31

基金资助

上海市浦东新区卫生局卫生（计生）科技项目（PW2013D-1）；上海市卫生和计划生育委员会面上项目（M20140513）

收起

Clinical efficacy of intravitreal injection of Conbercept in treatment of diabetic macular edema

  • SUN Qing-lei ,
  • YAN Yan ,
  • ZHU Li-na ,
  • QIN Xiao-ling ,
  • TAN Ye ,
  • LIU Jie ,
  • TAN Hai-bo ,
  • NING Li ,
  • LIU Lin
Expand

  • 1. Department of Ophthalmology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China; 2. Department of Ophthalmology, Lujiazui Community Health Service Center, Shanghai 200120, China; 3. Department of Ophthalmology, Gongli Hospital, Shanghai 200135, China; 4. Department of Ophthalmology, Weifang Community Health Center, Shanghai 200122, China

Online published: 2017-05-31

Supported by

Science and Technology Project of Health Bureau of Pudong New Area, Shanghai, PW2013D-1; Project of Shanghai Municipal Commission of Health and Family Planning General, M20140513

Fold

摘要

目的 ·评价玻璃体腔内注射抗血管内皮生长因子（VEGF）药物康柏西普对治疗糖尿病性黄斑水肿（DME）的临床效果。方法 ·选取DME（炎症型）患者11例17眼, 每月行1次康柏西普玻璃体腔内注射，首次治疗之后按需治疗。治疗结束后随诊6个月以上，比较治疗前后患者的最佳矫正视力（BCVA）、中央视网膜厚度（CRT）、DME消退率及眼底荧光血管造影检查（FFA）结果。结果 ·随访时间为7～29个月，平均（12±7）个月。注射针数1～10针，平均针数为（4±3）针。 DME患者注药后BCVA明显提高（t=7.306，P=0.001），CRT下降显著（t=5.272，P=0.000），差异有统计学意义。DME总消退率为76.5%。结论 ·玻璃体腔内注射抗VEGF药物康柏西普，可明显改善DME患者的视力，明显消退黄斑水肿症状。

关键词： 糖尿病性黄斑水肿; 康柏西普; 最佳矫正视力; 中央视网膜厚度

本文引用格式

孙清磊 , 闫焱 , 祝丽娜 , 秦晓玲 , 谭烨 , 刘洁 , 谭海波 , 宁利 , 柳林 . 康柏西普对糖尿病性黄斑水肿的疗效评价[J]. 上海交通大学学报（医学版）, 2017 , 37(5) : 652 . DOI: 10.3969/j.issn.1674-8115.2017.05.016

Abstract

Objective · To investigate the clinical effect of intravitreal injection of Conbercept in the treatment of diabetic macular edema (DME). Methods · Eleven patients (17 eyes) with DME (inflammatory type) received intravitreal injection of Conbercept monthly. After the first treatment, the patients were treated on demand. Follow-up after treatment for more than 6 months, the best corrected visual acuity (BCVA), central retinal thickness (CRT), diminished rate of DME and result of fundus fluorescein angiography(FFA) of DME eyes before and after treatment were compared. Results · During a follow-up of 7-29 months [(12±7) months], the injections were given 1-10 times [(4±3) times]. The results showed that the treatment effects on improving BCVA (logMAR) and diminishing of CRT were significant (t=7.306, P=0.001; t=5.272, P=0.000). The diminished rate of DME of our patients was 76.5%. Conclusion · Intravitreal injection of Conbercept in the treatment of DME is effective on reducing macular edema and improving visual acuity.

Key words： diabetic macular edema; Conbercept; the best corrected visual acuity; central retinal thickness

Options
文章导航

/

〈 〉